RTP Mobile Logo
What the Second Opinion Experiences of Clinical Investigators Tell Us About the Current Management of Non-Hodgkin Lymphomas and Multiple Myeloma
Released July 2012

Proceedings from a CME symposium held at the 2012 ASCO Annual Meeting. Featuring perspectives from Drs Steven M Horwitz, John P Leonard, Sagar Lonial, Antonio Palumbo, Mitchell R Smith and Sonali M Smith. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).

    OVERVIEW OF ACTIVITY

    There are currently more than 45 drug products labeled for use in the management of hematologic cancers with more than 55 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of tumor types.

    Practicing oncologists and their patients regularly turn to clinical investigators at academic and tertiary care centers for advice, answers and second opinions as they attempt to make the often complex and difficult clinical decisions they are confronting. In this capacity and through their roles as trusted educators, counselors and adjudicators, these experts observe patterns, develop insights and gain experiences that in totality represent a treasure trove of information that remains largely untapped. These proceedings from a CME symposium held at the 2012 ASCO Annual Meeting present the results of an in-depth assessment completed by 25 US-based MM clinical investigators and 25 NHL specialists regarding the most common second opinion cases they are referred. Also included are evidence-based presentations addressing the issues identified and rational “answers” to these common management ambiguities. This activity will use these perspectives to assist in the development of up-to-date clinical management strategies for MM and NHL that will be useful to hematologists, medical oncologists and other healthcare providers in the clinic.

    LEARNING OBJECTIVES

    • Develop a therapeutic algorithm for the clinical management of indolent and aggressive forms of B-cell NHL.
    • Explain the risks and benefits of evidence-based systemic agents to patients with advanced-stage cutaneous T-cell lymphoma warranting more intensive treatment.
    • Recognize the role of HDAC inhibitors, pralatrexate and other novel agents in the management of peripheral T-cell lymphoma, and ensure concurrent delivery of appropriate supplemental therapy to minimize side effects.
    • Apply the results of emerging clinical research to the selection of oral or intravenous cytotoxic and/or biologic regimens for patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
    • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
    • Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
    • Recall the ongoing clinical trials evaluating innovative investigational approaches for MM and NHL, and consent appropriate patients for study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Steven M Horwitz, MD
    Assistant Attending
    Lymphoma Service
    Division of Hematologic Oncology
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Advisory Committee: Allos Therapeutics, Celgene Corporation; Consulting Agreements: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Seattle Genetics, Spectrum Pharmaceuticals Inc; Paid Research: Allos Therapeutics, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Professor of Medicine
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company.

    Sagar Lonial, MD
    Professor
    Vice Chair of Clinical Affairs
    Director of Translational Research
    B-Cell Malignancy Program
    Department of Hematology and Medical Oncology
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Advisory Committee and Consulting Agreements: Acetylon Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Merck and Company Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

    Antonio Palumbo, MD

    Chief, Myeloma Unit
    Division of Hematology
    University of Torino
    Torino, Italy

    Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company; Speakers Bureau: Amgen Inc, Celgene Corporation, Millennium: The Takeda Oncology Company.

    Mitchell R Smith, MD, PhD
    Director, Lymphoma Service
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: Cephalon Inc; Speakers Bureau: Allos Therapeutics, Cephalon Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    Sonali M Smith, MD
    Associate Professor
    Section of Hematology/Oncology
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Advisory Committee: Celgene Corporation; Consulting Agreements: Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc; Paid Research: Allos Therapeutics, Celgene Corporation.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Allos Therapeutics, Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc and Teva.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2012
    Expiration date: July 2013

Acknowledge and close

Watch videos
(WiFi is recommended for best performance)
Introduction: Dr Love
Module 1:
Dr Lonial
Multiple Myeloma in the Transplant Setting
Module 2:
Dr Smith
Follicular Lymphoma
Module 3:
Dr Smith:
MCL and DLBCL
Module 4:
Dr Palumbo
MM in the Nontransplant Setting
Module 5:
Dr Horwitz
T-Cell Lymphoma
Module 6:
Dr Leonard
Chronic Lymphocytic Leukemia